CASSIOPEA S.P.A. - Download press release:
- EN
- DE
Lainate, Italy, February 4, 2022: Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") today announced that it has filed for delisting of its registered shares from SIX Swiss Exchange ("SIX"). Cassiopea has applied for a last trading day on March 4, 2022, which is subject to the approval by SIX.
About Cassiopea
Cassiopea is a specialty pharmaceutical company developing and commercializing prescription drugs with novel mechanisms of action to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. The Company's strategy is to leverage this expertise to optimize the commercial potential for its products with commercial partners. For further information on Cassiopea, please visit www.cassiopea.com.
Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Neither Cassiopea has any obligation to publicly update or revise any forward-looking statements.
Contact
Cassiopea SpA
| Pierpaolo Guzzo, | CEO |
| Tel | +39 02 868 911 24 |
| pguzzo@cassiopea.com |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Cassiopea S.p.A. published this content on 04 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 February 2022 05:05:03 UTC.
